Sildenafil Teva
From £3.99
Clinical Research Findings on Viagra Safety Profile
Pivotal Clinical Trial Evidence
The evidence base for Viagra's side effect profile stems from extensive clinical trials involving over 3,000 men before licensing. These double-blind, placebo-controlled studies revealed a predictable pattern of adverse events primarily related to sildenafil's vasodilatory effects. Research published in the International Journal of Impotence Research demonstrated that 16% of participants experienced headaches compared to 4% taking placebo, establishing this as the most statistically significant side effect.
Facial flushing occurred in 10% of trial participants, whilst dyspepsia affected 7% of users. These findings were consistent across multiple studies, providing robust evidence for prescribers and patients about expected side effect frequencies.
Cardiovascular Safety Research
Extensive cardiovascular research has been conducted given sildenafil's mechanism of action as a PDE5 inhibitor. A landmark study published in the American Journal of Cardiology followed 14,816 men with erectile dysfunction and found no increased risk of myocardial infarction compared to the general population. However, research consistently confirms absolute contraindications when combined with nitrates, where blood pressure drops can be life-threatening.
Clinical evidence supports safety in men with stable cardiovascular disease, though research indicates sexual activity itself may pose risks for some patients. Studies show that sildenafil's blood pressure lowering effect is modest in healthy individuals, typically reducing systolic pressure by 8-10mmHg.
Visual and Auditory Side Effects Research
Research into sildenafil's effects on vision stems from its weak inhibition of PDE6, an enzyme found in retinal photoreceptors. Clinical studies report visual disturbances in approximately 3% of users, typically manifesting as blue-tinted vision or light sensitivity. These effects are generally mild and reversible.
Post-marketing surveillance identified rare cases of sudden sensorineural hearing loss, prompting additional research. A case-control study suggested a possible association, though causation remains unproven. The incidence remains extremely low at fewer than 1 in 10,000 users.
Priapism Research and Risk Factors
Clinical research identifies priapism as Viagra's most serious potential side effect, though occurring in fewer than 1 in 1,000 users. Studies indicate higher risk in patients with sickle cell disease, multiple myeloma, or leukaemia. Research published in Urology demonstrates that prompt medical intervention within 4 hours typically prevents permanent damage.
Evidence suggests that priapism risk may be dose-dependent, with 100mg showing slightly higher incidence than 25mg or 50mg doses in clinical studies.
Long-term Safety Evidence
Long-term safety data spans over 25 years of clinical use worldwide. Research following patients for up to 7 years shows no evidence of tolerance development or cumulative toxicity. Studies indicate that side effect frequency often decreases with continued use as patients develop tolerance to vasodilatory effects.
Post-marketing surveillance data from millions of prescriptions confirms that serious adverse events remain rare, with the established side effect profile from original trials remaining accurate in real-world use.
Age-Related Side Effect Research
Clinical research demonstrates age-related differences in side effect profiles. Studies show older men (>65 years) experience similar side effect types but potentially increased sensitivity due to reduced drug clearance. Research indicates starting with 25mg in elderly patients reduces side effect incidence whilst maintaining efficacy.
Evidence suggests that comorbidities common in older patients, particularly cardiovascular disease and diabetes, may influence both effectiveness and side effect frequency.
Drug Interaction Research
Extensive pharmacokinetic research has identified clinically significant drug interactions. Studies demonstrate that CYP3A4 inhibitors like ketoconazole can increase sildenafil blood levels by 300%, necessitating dose reductions. Research confirms that alpha-blocker combinations require careful monitoring due to additive hypotensive effects.
Clinical evidence strongly supports absolute contraindication with nitrates, where research shows potentially fatal blood pressure drops can occur even with small nitrate doses.
